Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review

Min Deng; Huirong Chai; Meng Yang; Xueman Wei; Wenjun Zhang; Xuebin Wang; Juanjuan Li; Zhuo Wang; Haitao Chen

doi:10.3389/fonc.2021.736975

Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review

Front Oncol. 2021 Nov 17:11:736975. doi: 10.3389/fonc.2021.736975. eCollection 2021.

Authors

Min Deng^{1

2}, Huirong Chai³, Meng Yang³, Xueman Wei³, Wenjun Zhang³, Xuebin Wang², Juanjuan Li², Zhuo Wang^{1

2}, Haitao Chen³

Affiliations

¹ College of life sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, China.
² Department of Pharmacy, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
³ Department of Geriatrics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.

Abstract

Objective: Enzalutamide is the most frequently prescribed compound for treating metastatic castration-resistant prostate cancer (mCRPC). Common adverse drug events of enzalutamide are febrile neutropenia, hot flashes, hypertension, and fatigue.

Methods: We present a case of a patient with mCRPC who received enzalutamide and developed Stevens-Johnson syndrome (SJS). The culprit drug was confirmed using the Naranjo Adverse Drug Reaction Probability Scale. Clinical characteristics and management principles were analyzed in combination with literature reports.

Results: SJS occurred within two weeks of enzalutamide therapy. Supportive care such as steroid treatment led to a complete resolution of skin lesions and improved clinical symptoms after three weeks.

Conclusion: Most cutaneous adverse events occur early during enzalutamide therapy, and close observation should be given within two weeks of starting treatment.

Keywords: Stevens-Johnson syndrome; cutaneous adverse events; drug eruption; enzalutamide; prostate cancer.

Publication types

Case Reports